1,25-Dihydroxyvitamin D Inhibits the Proliferation of Rat Mesangial Cells Induced by High Glucose Via DDIT4

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Feb 9

PMID 29416624

Citations 5

Authors

Da-Peng Chen

Ye-Ping Ma

Li Zhuo

Zheng Zhang

Gu-Ming Zou

Yue Yang

Hong-Mei Gao

Wen-Ge Li

Affiliations

Soon will be listed here.

Abstract

1,25-Dihydroxyvitamin D(1,25(OH) D) is a secosteroid with antiproliferative property. It also plays a pivotal renoprotective role in diabetic nephropathy. We investigated whether 1,25(OH)D could inhibit the proliferation of rat mesangial cells exposed to high glucose via the DNA-damage-inducible transcript 4/mammalian target of rapamycin(DDIT4/mTOR) pathway. The cell proliferation rate and cell cycle duration were measured using cell counting kit-8 assay and flow cytometry. Protein expression was assayed by Western blot. Glucose acted as a growth factor in rat mesangial cells, promoted cell proliferation. In parallel, the protein expression of DDIT4, TSC1/TSC2, and 4E-BP1 were decreased, and Rheb, mTOR, and p70S6K were increased. Acting via the DDIT4/mTOR signaling, 1,25(OH) D treatment reversed these pathological changes, upregulated DDIT4, TSC1/TSC2, and 4E-BP1, downregulated Rheb, mTOR, and p70S6K. The short-term overexpression of DDIT4 inhibited the proliferation of rat mesangial cells, similar to 1,25(OH) D treatment. siRNA knockdown of DDIT4 suppressed antiproliferative responses to 1,25(OH) D. These results suggest that 1,25(OH) D inhibits the proliferation of rat mesangial cells induced by high glucose via the DDIT4/mTOR signaling pathway.

Citing Articles

mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets.

Shi J, Liu X, Jiao Y, Tian J, An J, Zou G Genes Dis. 2024; 12(2):101260.

PMID: 39717716 PMC: 11665407. DOI: 10.1016/j.gendis.2024.101260.

Unraveling DDIT4 in the VDR-mTOR pathway: a novel target for drug discovery in diabetic kidney disease.

Lu H, Jiao Y, Yu T, Shi J, Tian J, Zou G Front Pharmacol. 2024; 15:1344113.

PMID: 38567351 PMC: 10985261. DOI: 10.3389/fphar.2024.1344113.

Resveratrol improves palmitic acid‑induced insulin resistance via the DDIT4/mTOR pathway in C2C12 cells.

Pan X, Liu C, Wang X, Zhao M, Zhang Z, Zhang X Mol Med Rep. 2023; 28(4).

PMID: 37594055 PMC: 10463219. DOI: 10.3892/mmr.2023.13068.

Circulating levels of DDIT4 and mTOR, and contributions of BMI, inflammation and insulin sensitivity in hyperlipidemia.

Pan X, Zhang Z, Liu C, Zhao M, Wang X, Zhai J Exp Ther Med. 2022; 24(5):666.

PMID: 36168416 PMC: 9475340. DOI: 10.3892/etm.2022.11602.

Causal Links between Hypovitaminosis D and Dysregulation of the T Cell Connection of Immunity Associated with Obesity and Concomitant Pathologies.

Todosenko N, Vulf M, Yurova K, Khaziakhmatova O, Mikhailova L, Litvinova L Biomedicines. 2021; 9(12).

PMID: 34944566 PMC: 8698424. DOI: 10.3390/biomedicines9121750.

References

Ellisen L . Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle. 2005; 4(11):1500-02. DOI: 10.4161/cc.4.11.2139. View

Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J . Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol. 2014; 10(6):325-46. DOI: 10.1038/nrneph.2014.74. View

Kim S, Shevde N, Pike J . 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res. 2005; 20(2):305-17. DOI: 10.1359/JBMR.041112. View

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T . Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376(9752):1543-51. DOI: 10.1016/S0140-6736(10)61032-X. View

Plum L, Deluca H . Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010; 9(12):941-55. DOI: 10.1038/nrd3318. View

Lam J, Chow M, Zhang Y, Leung S . siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids. 2015; 4:e252. PMC: 4877448. DOI: 10.1038/mtna.2015.23. View

Chen D, Li Y, Mei Y, Geng W, Yang J, Hong Q . miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway. Cell Mol Life Sci. 2014; 71(20):4027-42. PMC: 4175047. DOI: 10.1007/s00018-014-1599-y. View

Lisse T, Liu T, Irmler M, Beckers J, Chen H, Adams J . Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 2010; 25(3):937-47. PMC: 3042839. DOI: 10.1096/fj.10-172577. View

Steffes M, Osterby R, Chavers B, MAUER S . Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989; 38(9):1077-81. DOI: 10.2337/diab.38.9.1077. View

10.

Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L . Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001; 60(1):87-95. DOI: 10.1046/j.1523-1755.2001.00775.x. View

11.

Yamagishi S, Matsui T . Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010; 3(2):101-8. PMC: 2952094. DOI: 10.4161/oxim.3.2.11148. View

12.

Usluogullari C, Balkan F, Caner S, Ucler R, Kaya C, Ersoy R . The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocr Disord. 2015; 15:33. PMC: 4480442. DOI: 10.1186/s12902-015-0029-y. View

13.

Singh D, Winocour P, Farrington K . Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol. 2010; 7(3):176-84. DOI: 10.1038/nrendo.2010.212. View

14.

Gao J, Wang F, Wang W, Su Z, Guo C, Cao S . Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. PLoS One. 2014; 9(4):e93588. PMC: 3972111. DOI: 10.1371/journal.pone.0093588. View

15.

Li R, Lou Y, Zhang W, Dong Q, Han B . Vitamin D inhibition of lung adenocarcinoma cell proliferation in vitro. Tumour Biol. 2014; 35(11):10953-8. DOI: 10.1007/s13277-014-1994-x. View

16.

Dennis M, Coleman C, Berg A, Jefferson L, Kimball S . REDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling. Sci Signal. 2014; 7(335):ra68. PMC: 4145530. DOI: 10.1126/scisignal.2005103. View

17.

Kanwar Y, Sun L, Xie P, Liu F, Chen S . A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011; 6:395-423. PMC: 3700379. DOI: 10.1146/annurev.pathol.4.110807.092150. View

18.

Tuttle K, Bakris G, Bilous R, Chiang J, de Boer I, Goldstein-Fuchs J . Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014; 64(4):510-33. DOI: 10.1053/j.ajkd.2014.08.001. View

19.

Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R . The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 2009; 384(4):471-5. DOI: 10.1016/j.bbrc.2009.04.136. View

20.

Zhuo L, Fu B, Bai X, Zhang B, Wu L, Cui J . NAD blocks high glucose induced mesangial hypertrophy via activation of the sirtuins-AMPK-mTOR pathway. Cell Physiol Biochem. 2011; 27(6):681-90. DOI: 10.1159/000330077. View